Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
(World News USA)

Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin Approximately 80-95 percent editing was achieved in CD34+ cells Increased fetal hemoglobin levels were sustained for at least 16 weeks following transplant in mice ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. ( NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis, presented initial data from their research collaboration on genome-edited human hematopoietic stem cells. These data showed successfulex vivo editing of the erythroid specific...